✉ Email this page to a colleague
« Back to Dashboard
Apaziquone is an investigational drug.
There have been 9 clinical trials for Apaziquone. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms and [disabled in preview]. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Handok Inc., and Handok Pharmaceuticals Co., Ltd.
Recent Clinical Trials for Apaziquone
|A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)||Spectrum Pharmaceuticals, Inc||Phase 3|
|A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)||Spectrum Pharmaceuticals, Inc||Phase 3|
|Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)||Allergan||Phase 3|